Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose daily versus weekly pulse isotretinoin for moderate acne vulgaris
ACTRN12625000983404Phase 3Not yet recruiting
- Sponsor
- PNS Shifa
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of isotretinoin in acne vulgaris (2 arms), sponsored by PNS Shifa. Primary endpoints: Treatment response by standardized acne rating scale at 24 weeks and Photographic acne assessment at 6 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
isotretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ACTRN12625000983404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000983404.